The choice of the chelating fragment of bifunctional ligand depends on the nature and oxidation state of the radiometal. There are numerous examples in the literature, which show that the nature of a bifunctional metal complex such as geometry, lipophilicity, overall charge plays a crucial role in determining the biodistribution of targeted radiopharmaceuticals. Furthermore, in designing of novel radiopharmaceuticals energy of the radionuclide should be taken into account. Cyclen and cyclam based macrocycles are known to form kinetically inert and thermodynamically stable complexes with a wide range of metal ions. Several classes of structurally different phosphonate ligands labeled with β emitting radionuclides such as 166Ho-DOTMP complex are being used clinically for the treatment of painful bone metastases. The choice of used cyclic chelating agents is also based on the more pronounced thermodynamic stability and kinetic inertness of their lanthanide complexes when compared to that of their acyclic analog. The physical, magnetic and nuclear properties of the lanthanide ions have made them ideal for use in both diagnostic and therapeutic radiopharmaceuticals. The aim of this work was to prepare bifunctional ligands based on cyclen and cyclam structures, test their labelling conditions with europium as a model radionuclide, in order to develop potential new radiopharmaceuticals. Through this aim, cyclen and selected tetraphosphonate derivative of cyclam (TETP) were synthesized. Obtained data show that all used ligands, DOTA, TETP, NOTA and TRAP-Pr, form complexes with Eu(III) at 95 °C and in the pH range from 2 to 6. They also show excellent kinetic stability at pH 4.